Nyrada, Inc. · ASX:NYR
Nyrada — Investor Presentation (October 2024)
18 slides from Nyrada's investor presentation, Oct 4, 2024
Slide 1: Investor Presentation October 2024
For personal use only Investor Presentation October 2024 Improving Lives, Offering Hope Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board. ASX:NYR
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should not Although the Company believes that the expectations reflected in the forward-looking For personal use only be considered as an offer or invitation to subscribe for, or purchase any s
Slide 3: About Nyrada
About Nyrada › Drug discovery and development company specialising in rational design of novel small molecule therapeutics. For personal use only › Nyrada’s lead drug candidate NYR-BI03: › demonstrated strong preclinical efficacy protecting the brain from secondary injury following stroke. › demonst
Slide 4: Investment Proposition
Investment Proposition › Pioneering transient receptor potential canonical (TRPC) For personal use only channel blocking therapies. › First-in-class neuroprotection therapy with novel mode of action. › Cardioprotection therapy with superior performance to Captopril, an FDA approved ACE inhibitor. ›
Slide 5: One Drug, Two Applications, Three Markets
One Two Three Drug Applications Markets For personal use only STROKE NYR-BI03 Neuroprotection GLP data package ~US$52.2 billion by 20322 nearing completion Approaching Phase I TRAUMATIC BRAIN INJURY clinical trial in 4QCY2024 ~US$5.5 billion by 20344 Cardioprotection MYOCARDIAL INFARCTION ~US$3.7 bi
Slide 6: Neuroprotection – Stroke and TBI
Neuroprotection – Stroke and TBI Serial reconstruction from MRI For personal use only Secondary Disability Primary Injury Injury Level 30 mins BECAME STAYED THE DIED WORSE SAME IMPROVED 72 hours Hours Days Weeks Months Reduce secondary injury resulting from stroke or TBI Nyrada drug NYR-BI03 • Impro
Slide 7: Cardioprotection
Cardioprotection Key Preclinical Results: NYR-BI03 showed strong efficacy For personal use only limiting cardiovascular damage associated with coronary heart disease 86% Cardioprotection following myocardial ischemic- reperfusion injury Superior efficacy Compared to FDA-approved, Captopril 7
Slide 8: GLP Safety Studies
GLP Safety Studies Approaching Conclusion For personal use only GLP Study Reported AMES 16 July 2024 hERG 16 July 2024 Rat CNS 06 August 2024 Rat Respiratory 20 August 2024 Dog cardiovascular safety 09 September 2024 14-day dog toxicology 27 September 2024 14-day rat toxicology In vitro micronucleus
Slide 9: Near Term Catalysts
Near Term Catalysts Catalysts Early to Mid 4QCY2024 For personal use only NYR-BI03 GLP study updates › 2HCY2024 – NYR-BI03 GLP study updates Mid 4QCY2024 › 3QCY2024 – WRAIR TBI study update NYR-BI03 Human Research Ethics application submission › 4QCY2024 – NYR-BI03 Human Research Ethics application
Slide 10: Appendices
For personal use only Appendices 10
Slide 11: Indicative Phase I Study Design
Indicative Phase I Study Design For personal use only OBJECTIVES To assess the safety, tolerability, and pharmacokinetics of NYR-BI03 DESIGN • Randomised, double-blind PARTICIPANTS placebo –controlled, dose escalation design • Male and female healthy volunteers • 5 cohorts; 8 participants each • 18
Slide 12: Large Market Opportunity – Stroke
Large Market Opportunity – Stroke For personal use only Globally: ~15 million ~5 million people suffer strokes left permanently annually1 disabled1 One approved drug class for stroke suitable for <15% of patients (tPA - tissue plasminogen activator). Effective treatment will improve patient outcomes
Slide 13: Large Market Opportunity – Traumatic Brain Injury (TBI)
Large Market Opportunity – Traumatic Brain Injury (TBI) For personal use only Globally: ~5.5 million ~55 million people suffer severe living with effects of TBA annually3 medically treated TBI3 No current FDA approved treatments Effective treatment will improve patient outcomes and reduce high costs
Slide 14: Nyrada's Lead Drug Candidate NYR-BI03
Nyrada’s Lead Drug Candidate NYR-BI03 For personal use only First-in-Class with Novel Significant Unmet Clinical Need Mechanism of Action and Market Opportunity › NYR-BI03 is a first-in-class therapy. › Targeting multiple indications. › Novel mechanism of action. › Stroke, TBI and Cardiac heart dise
Slide 15: Management Team with Proven Industry Experience
Management Team with Proven Industry Experience For personal use only James Bonnar - CEO Cameron Jones - CFO Dr Benny Evison - CSO Supported by specialist advisers: › Business executive with 25 years › Finance executive with experience as › More than 20 years of experience of experience in healthcar
Slide 16: High Calibre Board with international experience
High Calibre Board with international experience For personal use only › Nyrada operates under the direction of a governing board of international calibre John Moore Dr Ian Dixon Dr Gisela Mautner › Strong track record in realising the Non-Executive Chair Non-Executive Director Non-Executive Directo
Slide 17: References
References 1 – World Health Organization - https://www.emro.who.int/health-topics/stroke-cerebrovascular- For personal use only accident/index.html#:~:text=Annually%2C%2015%20million%20people%20worldwide,cause%20i s%20high%20blood%20pressure 2 – Databridge Market Research - https://www.databridgemar
Slide 18: Brain Injury Solution Animation
Brain Injury Solution Animation For personal use only Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board. @nyrada_inc @nyrada_inc info@nyrada.com www.nyrada.com 18